Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.38 |
| ▸ | FURIN | P09958 | 9/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19026282 | 1.00 | FAP (0.38) | FAPFURINC3AR1MAP1LC3BHTT | |
| SCHEMBL18931388 | 1.00 | FAP (0.38) | FAPFURINC3AR1MAP1LC3BHTT | |
| SCHEMBL16946352 | 0.94 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL27197502 | 0.94 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL22138625 | 0.94 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL25450085 | 0.94 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL23943282 | 0.94 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL24224636 | 0.94 | FAP (0.40) | FAPFURINMAP1LC3BHTTSMN1; SMN2 | |
| SCHEMBL16273810 | 0.94 | FAP (0.41) | FAPFURINMAP1LC3B | |
| SCHEMBL16266199 | 0.94 | FAP (0.41) | FAPFURINMAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3888689-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3735990-A1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | Abbvie Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2020-08-06 | — | — | US | disclosed |
| EP-3229844-B1 | ANTIBODY DRUG CONJUGATES WITH CELL PERMEABLE BCL-XL INHIBITORS | ABBVIE INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3468993-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | ABBVIE INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199745-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | FAP 4493/4885FURIN 2449/4885C3AR1 1616/4885 |
| US-20170182179-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | FAP 3670/4885FURIN 4004/4885C3AR1 4033/4885 |
| US-20190153107-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | FAP 4493/4885FURIN 2449/4885C3AR1 1616/4885 |
| US-20200246323-A1 | Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors | BCL2, BCL2L10, BAX | FAP 3670/4885FURIN 4004/4885C3AR1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.